3-benzyloxy-2-(4-benzyloxy-3,5-dimethoxy-phenyl)-7-(3,7-dimethyl-octyl)-chromen-4-one | 649551-82-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3-benzyloxy-2-(4-benzyloxy-3,5-dimethoxy-phenyl)-7-(3,7-dimethyl-octyl)-chromen-4-one
• 英文别名: 2-(3,5-dimethoxy-4-phenylmethoxyphenyl)-7-(3,7-dimethyloctyl)-3-phenylmethoxychromen-4-one
• CAS: 649551-82-6
• 化学式: C₄₁H₄₆O₆
• 分子量: 634.813
• InChiKey: WEFAUKLIJMTZDD-UHFFFAOYSA-N

物化性质

• 沸点：
  748.9±60.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.8
• 重原子数：
  47
• 可旋转键数：
  16
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  63.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-2-(4-benzyloxy-3,5-dimethoxy-phenyl)-7-(3,7-dimethyl-octyl)-chromen-4-one 在 三溴化硼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 25.0h， 以37%的产率得到7-(3,7-dimethyl-octyl)-3-hydroxy-2-(3,4,5-trihydroxy-phenyl)-chromen-4-one
  参考文献：
  名称：

  [EN] FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS
  [FR] COMPOSES FLAVONOIDES EN TANT QU'ANTIOXYDANTS THERAPEUTIQUES

  摘要：

  描述了具有抗氧化活性的新型黄酮类化合物。公式（1）。已经证明这些化合物在生物系统中展现出抗氧化特性，其在防晒霜或护肤品中的用途，或用于治疗涉及氧化损伤的情况，特别是治疗或预防治疗阿尔茨海默病或缺血再灌注和损伤的情况。

  公开号：

  WO2004007475A1
• 作为产物：
  描述：

  1-(2-羟基-4-碘苯基)乙酮 在 氢氧化钾 、 sodium hydroxide 、 双氧水 、 potassium carbonate 、 magnesium 、 potassium iodide 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 丙酮 为溶剂， 反应 134.0h， 生成 3-benzyloxy-2-(4-benzyloxy-3,5-dimethoxy-phenyl)-7-(3,7-dimethyl-octyl)-chromen-4-one
  参考文献：
  名称：

  Potential therapeutic antioxidants that combine the radical scavenging ability of myricetin and the lipophilic chain of vitamin E to effectively inhibit microsomal lipid peroxidation

  摘要：

  The flavonol myricetin, reacts with oxygen-centred galvinoxyl radicals 28 times faster than d-alpha-tocopherol (vitamin E), the main lipid-soluble antioxidant in biological membranes. Moreover, each myricetin molecule reduces twice as many such radicals as vitamin E. However, myricetin fails to protect vitamin E-deficient microsomes from lipid peroxidation as assessed by the formation of thiobarbituric acid reactive substances (TBARS). Novel and potentially therapeutic antioxidants have been prepared that combine the radical-scavenging ability of a myricetin-like head group with a lipophilic chain similar to that of vitamin E. C-6-C-12 alkyl chains are attached to the A-ring of either a 3,3',4',5'-tetrahydroxyflavone or a 3,2',4',5'-tetrahydroxyflavone head group to give lipophilic flavonoids (Clog P = 4 to 10) that markedly inhibit iron-ADP catalysed oxidation of microsomal preparations. Orientation of the head group as well as total lipophilicity are important determinants of antioxidant efficacy. MM2 models indicate that our best straight chain 7-alkylflavonoids embed to the same depth in the membrane as vitamin E. The flavonoid head groups are prepared by aldol condensation followed by Algar-Flynn-Oyamada (AFO) oxidation or by Baker-Venkataraman re-arrangement. The alkyl tails are introduced by Suzuki or Negishi palladium-catalysed cross-coupling or by cross-metathesis catalysed by first generation Grubbs catalyst, which tolerate phenolic hydroxyl and ketone groups. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.02.031

文献信息

• [EN] FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS<br/>[FR] COMPOSES FLAVONOIDES EN TANT QU'ANTIOXYDANTS THERAPEUTIQUES
  申请人：ROWETT RES INST

  公开号：WO2004007475A1

  公开（公告）日：2004-01-22

  Novel flavonoid compounds having anti-oxidant activity are described. Formula (1). The compounds have been shown to exhibit anti-oxidative properties in biological systems and their utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease or ischaemia-reperfusion and injury, is described.

  描述了具有抗氧化活性的新型黄酮类化合物。公式（1）。已经证明这些化合物在生物系统中展现出抗氧化特性，其在防晒霜或护肤品中的用途，或用于治疗涉及氧化损伤的情况，特别是治疗或预防治疗阿尔茨海默病或缺血再灌注和损伤的情况。
• Flavonoid compounds as therapeutic antioxidants
  申请人：Caldwell Thomas Stuart

  公开号：US20060137207A1

  公开（公告）日：2006-06-29

  Novel flavonoid compounds having anti-oxidant activity are described. Formula 1. The compounds have been shown to exhibit anti-oxidative properties in biological systems and their utility in a sunscreen or skincare composition or to treat conditions involving oxidative damage, especially curative or prophylactic treatment of Alzheimer's disease or ischaemia-reperfusion injury, is described.

  描述了具有抗氧化活性的新型黄酮类化合物。公式1。已经证明这些化合物在生物系统中表现出抗氧化性质，并描述了它们在防晒霜或护肤组合物中的实用性，或用于治疗涉及氧化损伤的疾病，特别是治疗阿尔茨海默病或缺血再灌注损伤的治疗或预防。
• FLAVONOID COMPOUNDS AS THERAPEUTIC ANTIOXIDANTS
  申请人：The Rowett Research Institute

  公开号：EP1534698B1

  公开（公告）日：2007-09-19
• US7601754B2
  申请人：——

  公开号：US7601754B2

  公开（公告）日：2009-10-13
• Potential therapeutic antioxidants that combine the radical scavenging ability of myricetin and the lipophilic chain of vitamin E to effectively inhibit microsomal lipid peroxidation
  作者：Christopher J. Bennett、Stuart T. Caldwell、Donald B. McPhail、Philip C. Morrice、Garry G. Duthie、Richard C. Hartley

  DOI：10.1016/j.bmc.2004.02.031

  日期：2004.5

  The flavonol myricetin, reacts with oxygen-centred galvinoxyl radicals 28 times faster than d-alpha-tocopherol (vitamin E), the main lipid-soluble antioxidant in biological membranes. Moreover, each myricetin molecule reduces twice as many such radicals as vitamin E. However, myricetin fails to protect vitamin E-deficient microsomes from lipid peroxidation as assessed by the formation of thiobarbituric acid reactive substances (TBARS). Novel and potentially therapeutic antioxidants have been prepared that combine the radical-scavenging ability of a myricetin-like head group with a lipophilic chain similar to that of vitamin E. C-6-C-12 alkyl chains are attached to the A-ring of either a 3,3',4',5'-tetrahydroxyflavone or a 3,2',4',5'-tetrahydroxyflavone head group to give lipophilic flavonoids (Clog P = 4 to 10) that markedly inhibit iron-ADP catalysed oxidation of microsomal preparations. Orientation of the head group as well as total lipophilicity are important determinants of antioxidant efficacy. MM2 models indicate that our best straight chain 7-alkylflavonoids embed to the same depth in the membrane as vitamin E. The flavonoid head groups are prepared by aldol condensation followed by Algar-Flynn-Oyamada (AFO) oxidation or by Baker-Venkataraman re-arrangement. The alkyl tails are introduced by Suzuki or Negishi palladium-catalysed cross-coupling or by cross-metathesis catalysed by first generation Grubbs catalyst, which tolerate phenolic hydroxyl and ketone groups. (C) 2004 Elsevier Ltd. All rights reserved.